Could a diabetes drug tame PCOS inflammation better than standard care?
NCT ID NCT05966792
First seen Apr 30, 2026 · Last updated May 11, 2026 · Updated 4 times
Summary
This study looked at whether a newer diabetes drug, called an SGLT2 inhibitor, can improve symptoms of Polycystic Ovary Syndrome (PCOS) better than the standard drug metformin. PCOS involves chronic inflammation, and the SGLT2 inhibitor may work by reducing that inflammation. The trial included 82 women with PCOS and compared the effects of the two drugs on menstrual cycles and other health markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC OVARY SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Tenth People'S Hospital
Shanghai, Shanghai Municipality, 200072, China
Conditions
Explore the condition pages connected to this study.